Viking sets sail with 5 Ligand assets
This article was originally published in Scrip
Viking Therapeutics licensed five assets from Ligand Pharmaceuticals, including a clinical-stage type 2 diabetes program that the private San Diego-based company has been working on since it was founded in late 2012.
You may also be interested in...
The company's oral non-steroidal SARM could be the first approved drug to help patients maintain muscle after hip fracture surgery, but will FDA seek pivotal data on muscle mass or on functional measures?
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.